In conclusion, although we did not find consistent data regarding the impact of FLT3 mutations or elevated FLT3 expression levels on patient response (measured by MRD values after induction) or relapse rates, our findings suggest that FLT3 alterations — whether genetic or expression-related —exert a biological influence on the behavior of leukemic cells and may complement traditional tools used to enhance B-ALL characterization. This evidence concerns the gene FLT3 and acute lymphoblastic leukemia.